234080.KS
JW Lifescience Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 11,200.00
−1.67%Year over year
Reported trailing growth
- Revenue
- +4.1%
- EBITDA
- -42.6%
- EBIT
- -11.0%
- EPS
- -47.4%
- Free cash flow
- -19.9%
- Operating cash flow
- -14.9%
Forward estimates
Based on analyst estimates
- Revenue
- -46.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.9%
- EBITDA
- +5.5%
- EBIT
- +7.1%
- Net income
- +24.1%
- EPS
- +24.1%
- Free cash flow
- +68.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026